Clinical trials: Sorafenib
Healthy, Male
Study to Compare Pharmacokinetic Property of SYO-1644 Tab. and Nexavar Tab. in Healthy Male Volunteers
The purpose of this study is to evaluate the pharmacokinetics characteristics ,tolerability, and safety after orally administrating SYO-1644 to healthy male volunteers in randomized, active-controlled, open-label clinical study.
- Trial name
- NCT03674060
- Testing
- SYO-1644, Nexavar tab
- Where
- South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Samyang Biopharmaceuticals Corporation
Sarcopenia
Influence of Sarcopenia in Hepatocellular Carcinoma Patients
Liver cancer poses a major threat to the global cancer burden, and the number of deaths is estimated to be more than one million annually by 2030.
- Trial name
- NCT06177496
- Testing
- local ablation, TACE, Sorafenib
- Volunteers
- 600 people
- Sponsor
- Sohag University
Hepatocellular Carcinoma (HCC)
A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)
This Phase 3 study was a global, multicenter trial that randomly assigned participants to either tislelizumab or sorafenib as a first-line treatment for adults with advanced liver cancer (hepatocellular carcinoma) that could not…
- Trial name
- NCT03412773
- Testing
- Tislelizumab, Sorafenib
- Where
- 122 sites in United States, China and 9 more
- Volunteers
- 684 people
- Sponsor
- BeiGene
Metastatic Renal Cell Carcinoma
MRI Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma
The purpose of this study is to determine maximum tumor shrinkage, time to progression, survival, drug concentration, and degree of skin toxicity.
- Trial name
- MRI (NCT00606866)
- Testing
- Sorafenib
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- University of Chicago
Kidney Cancer
Sorafenib in Treating Patients Undergoing Surgery for Stage II, Stage III, or Stage IV Kidney Cancer
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NRR (NCT00405366)
- Testing
- sorafenib tosylate
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancer
Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer
This phase II trial is studying how well giving sorafenib together with docetaxel and cisplatin works in treating patients with metastatic or locally advanced gastric or gastroesophageal junction cancer that cannot be removed by…
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancer, Advanced Unresectable Gastric Cancer
- Trial name
- NCT00253370
- Testing
- BAY 43-9006, docetaxel, cisplatin
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Renal Cell Carcinoma
Study of Sorafenib in Patients With Advanced Renal Cell Carcinoma
The purpose study is to evaluate the efficacy and safety of Sorafenib as first line treatment for patients - unsuitable for another approved first line therapy - with advanced RCC in the Middle East Region.
- Trial name
- MERITS (NCT00848640)
- Testing
- Sorafenib
- Where
- Egypt
- Volunteers
- 75 people
- Sponsor
- Egyptian Foundation For Cancer Research
Colorectal Neoplasms
Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal Cancer
The purpose of this study is to determine whether sorafenib in combination with chemotherapy has a positive effect on time to progression of the tumor or death for the treatment of large bowel cancer that has already progressed…
- Trial name
- FOSCO (NCT00889343)
- Testing
- Sorafenib, Oxaliplatin or Irinotecan, Leucovorin
- Where
- 57 sites in Germany
- Volunteers
- 101 people
- Sponsor
- AIO-Studien-gGmbH
Renal Cancer, Non Small Cell Lung Cancer (NSCLC)
Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers
The purpose of this study is to determine if a new investigational drug called Panobinostat is safe, tolerable and to obtain an initial assessment of efficacy, when given in combination with Sorafenib for the treatment of certain…
- Conditions
- Renal Cancer, Non Small Cell Lung Cancer (NSCLC), Soft Tissue Sarcoma
- Trial name
- NCT01005797
- Testing
- Panobinostat (LBH589), Sorafenib
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Medical University of South Carolina
Hepatocellular Carcinoma
Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy
The purpose of this study is to determine whether TAC-101 as a second line therapy for participants who received Sorafenib as first line therapy is effective in slowing tumor activity in patients with advanced hepatocellular…
- Trial name
- NCT00687596
- Testing
- TAC-101
- Where
- Italy
- Volunteers
- 52 people
- Sponsor
- Taiho Oncology, Inc.
Radiotherapy, Toripalimab
Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT
To explore the efficacy of radiotherapy plus toripalimab Versus standard treatment of sorafenib in advanced hepatocellular carcinoma with Portal Vein/Hepatic vein Tumor Thrombosis.
- Conditions
- Radiotherapy, Toripalimab, Sorafenib, Advanced Hepatocellular Carcinoma
- Trial name
- NCT04709380
- Testing
- Radiotherapy plus Toripalimab, Sorafenib
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences